Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18984398 | METHOD FOR GENERATING GENOME-EDITED CHICKENS | December 2024 | June 2025 | Allow | 6 | 1 | 0 | Yes | No |
| 18948566 | GENETICALLY MODIFIED RAT HAVING PKHD1L1 GENE WITH POINT MUTATION AND METHODS FOR ITS CONSTRUCTION, DETECTION AND USE | November 2024 | February 2026 | Allow | 15 | 2 | 1 | Yes | No |
| 18612882 | ENGINEERED CLASS 2, TYPE V REPRESSOR SYSTEMS | March 2024 | September 2025 | Allow | 18 | 3 | 1 | No | No |
| 18381652 | VASCULARIZED CARDIAC ORGANOID WITH A CHAMBER STRUCTURE AND ITS PREPARATION METHOD | October 2023 | September 2024 | Allow | 11 | 1 | 0 | Yes | No |
| 18484279 | VIRAL EXPRESSION CONSTRUCT COMPRISING A FIBROBLAST GROWTH FACTOR 21 (FGF21) CODING SEQUENCE | October 2023 | August 2025 | Allow | 22 | 2 | 1 | Yes | No |
| 18134892 | METHODS AND COMPOSITIONS FOR INDUCING TUMOR CELL DEATH | April 2023 | October 2024 | Abandon | 18 | 0 | 1 | No | No |
| 18062471 | SYSTEMS AND METHODS FOR CELL CONVERSION | December 2022 | February 2026 | Abandon | 38 | 1 | 0 | No | No |
| 17914074 | TARGETING TAPASIN AND TAP COMPLEX TO IMPROVE CELLULAR IMMUNE-COMPATIBILITY | September 2022 | January 2026 | Abandon | 40 | 0 | 1 | No | No |
| 17801736 | A Method For Providing A Cartilage Implant With Chondrocytes | August 2022 | January 2026 | Abandon | 41 | 0 | 1 | No | No |
| 17819547 | PRECISE TEMPLATE-FREE CORRECTION OF BRCA1 MUTATION IN HUMAN CELLS VIA GENOME EDITING | August 2022 | December 2025 | Abandon | 40 | 3 | 1 | No | No |
| 17782148 | METHODS OF MEAT PRODUCTION BY IN VITRO CELL CULTIVATION | June 2022 | December 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17773080 | VIABLE PANCREATIC ISLET-LIKE CELL STRUCTURES AND A METHOD OF PREPARING THEREOF | April 2022 | November 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17770727 | GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC GENES | April 2022 | November 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17720753 | MODIFIED INDUCED PLURIPOTENT STEM CELL (iPSC) DERIVED MICROGLIA FOR THE TREATMENT OF BRAIN CANCER | April 2022 | March 2024 | Abandon | 23 | 0 | 1 | No | No |
| 17697168 | METHOD AND COMPOSITION FOR CHONDROGENESIS | March 2022 | January 2024 | Abandon | 22 | 0 | 1 | No | No |
| 17761190 | A METHOD OF ENGINEERING NATURAL KILLER-CELLS TO TARGET BCMA-POSITIVE TUMORS | March 2022 | November 2025 | Abandon | 44 | 0 | 1 | No | No |
| 17675895 | ATRIAL CARDIAC MICROTISSUES FOR CHAMBER-SPECIFIC ARRHYTHMOGENIC TOXICITY RESPONSES | February 2022 | September 2025 | Abandon | 42 | 3 | 1 | No | No |
| 17636235 | COMPOSITIONS AND METHODS FOR NEUROLOGICAL DISEASES | February 2022 | October 2025 | Abandon | 43 | 1 | 1 | No | No |
| 17631928 | BIOLOGICAL COMPONENT TREATMENT SYSTEM, BIOLOGICAL COMPONENT TREATMENT DEVICE, AND CELL CULTURING METHOD | February 2022 | August 2025 | Allow | 42 | 1 | 1 | Yes | No |
| 17589840 | COMPOSITIONS AND METHODS FOR PRODUCING STABLE VIRAL VECTOR PRODUCER CELLS FOR CELL AND GENE THERAPY | January 2022 | September 2025 | Abandon | 44 | 1 | 0 | No | No |
| 17568032 | METHOD AND COMPOSITION FOR SORTING OUT OF CELL COMPRISING A MODIFIED GENE | January 2022 | August 2023 | Allow | 19 | 1 | 1 | No | No |
| 17555550 | NON-HUMAN ANIMALS HAVING A HUMANIZED TSLP GENE, A HUMANIZED TSLP RECEPTOR GENE, AND/OR A HUMANIZED IL7RA GENE | December 2021 | July 2025 | Abandon | 43 | 4 | 1 | No | No |
| 17539253 | DECIDUAL PLACENTAL MESENCHYMAL STEM CELL AND THE USE OF THE CELL FOR PREPARING PHARMACEUTICAL COMPOSITIONS FOR PROMOTING ANGIOGENESIS | December 2021 | February 2024 | Allow | 26 | 3 | 0 | No | No |
| 17525312 | THERAPEUTIC METHODS AND COMPOSITIONS UTILIZING STROMAL VASCULAR FRACTION DERIVED FROM ADIPOSE TISSUE | November 2021 | November 2025 | Allow | 48 | 3 | 1 | No | No |
| 17490449 | RODENT ANIMALS EXPRESSING HUMAN CR1 | September 2021 | March 2024 | Allow | 29 | 2 | 1 | Yes | No |
| 17483100 | GENETICALLY ENGINEERED T CELLS WITH REGNASE-1 AND/OR TGFBRII DISRUPTION HAVE IMPROVED FUNCTIONALITY AND PERSISTENCE | September 2021 | June 2025 | Abandon | 44 | 4 | 1 | No | No |
| 17440488 | METHOD FOR TREATING ATOPIC DERMATITIS USING MONOCLONAL STEM CELLS | September 2021 | July 2025 | Abandon | 45 | 1 | 1 | No | No |
| 17460120 | SYNTHETIC MAMMALIAN SIGNALING CIRCUITS FOR ROBUST CELL POPULATION CONTROL | August 2021 | January 2024 | Allow | 29 | 2 | 1 | Yes | No |
| 17409265 | HUMANIZED MOUSE MODEL SUSCEPTIBLE TO EMERGING CORONAVIRUSES | August 2021 | June 2024 | Abandon | 33 | 2 | 1 | No | No |
| 17406723 | ADENO-ASSOCIATED VIRUS VECTORS FOR TREATMENT OF RETT SYNDROME | August 2021 | May 2024 | Allow | 33 | 2 | 1 | Yes | No |
| 17377318 | Synthesis of Non-Native Proteins in Bombyx Mori by Modifying Sericin Expression | July 2021 | May 2024 | Abandon | 34 | 2 | 1 | No | No |
| 17346948 | METHODS FOR PRODUCING FIBROADIPOGENIC PROGENITOR CELLS | June 2021 | October 2024 | Allow | 40 | 3 | 0 | No | No |
| 17326708 | GENETICALLY ENGINEERED CAR T CELLS THAT SECRETE INTERLEUKIN-12 AND THERAPEUTIC USES THEREOF | May 2021 | January 2025 | Abandon | 44 | 3 | 1 | Yes | No |
| 17291667 | Use of oligodendrocytes from oral neuroectodermal stem cells in the repair of the nervous system | May 2021 | April 2024 | Abandon | 36 | 1 | 1 | No | No |
| 17308154 | HANGING DROP DEVICE, FORMATION METHOD OF HANGING DROP AND CELL CULTURE METHOD BY USING HANGING DROP | May 2021 | September 2023 | Allow | 28 | 2 | 1 | No | No |
| 17288674 | METHOD FOR PRODUCING INSULIN-PRODUCING CELLS | April 2021 | January 2026 | Abandon | 56 | 4 | 1 | Yes | No |
| 17288253 | Method for Producing Virus-Infected Cell Line and Animal Model | April 2021 | November 2024 | Abandon | 43 | 0 | 1 | No | No |
| 17287480 | CLEAVABLE ACTIVATORS OF CXCR3 AND METHODS OF USE | April 2021 | June 2024 | Allow | 38 | 2 | 1 | Yes | No |
| 17232676 | COMPOSITIONS AND METHODS FOR SEQUESTERING VIRUSES | April 2021 | July 2025 | Abandon | 51 | 4 | 1 | No | No |
| 17199115 | Gene Therapy for NMNAT1-Associated Retinal Degeneration | March 2021 | August 2024 | Allow | 41 | 4 | 0 | No | No |
| 17190650 | A RODENT MODEL OF B4GALT1-MEDIATED FUNCTIONS | March 2021 | March 2025 | Abandon | 49 | 3 | 1 | Yes | Yes |
| 17270349 | CELL CLUSTER INCLUDING OLFACTORY NEURON OR PRECURSOR CELL THEREOF, AND METHOD FOR PRODUCING SAME | February 2021 | July 2024 | Abandon | 40 | 1 | 1 | No | No |
| 17175234 | HAPLOTYPE-BASED TREATMENT OF RP1 ASSOCIATED RETINAL DEGENERATIONS | February 2021 | June 2024 | Allow | 40 | 2 | 1 | Yes | No |
| 17173887 | GENERATING INDUCED PLURIPOTENT STEM CELLS | February 2021 | October 2025 | Abandon | 56 | 2 | 1 | No | Yes |
| 17161269 | GENERATION OF INDUCED PLURIPOTENT STEM CELLS (IPSCs) WITH GLUT2 MUTATION OR FOXA2 DELETION, METHODS OF PREPARING SAME, AND METHODS OF USING SAME | January 2021 | December 2024 | Allow | 47 | 4 | 1 | Yes | No |
| 17150959 | INDUCTION OF DNA STRAND BREAKS AT CHROMATIN TARGETS | January 2021 | April 2024 | Abandon | 39 | 2 | 1 | No | No |
| 17150562 | SINGLE ADENO-ASSOCIATED VIRUS (AAV)-SIZED NUCLEOTIDE FOR USE IN CRISPR INTERFERENCE OR ACTIVATION | January 2021 | December 2023 | Allow | 35 | 3 | 0 | Yes | No |
| 17139471 | PROGRAMMABLE AND PORTABLE CRISPR-CAS TRANSCRIPTIONAL ACTIVATION IN BACTERIA | December 2020 | July 2023 | Allow | 30 | 1 | 1 | No | No |
| 17136080 | COMPOSITION AND METHOD FOR PREVENTING OR TREATING EYE DISORDER | December 2020 | April 2024 | Allow | 39 | 4 | 0 | No | No |
| 17122087 | ENGINEERED BI-STABLE TOGGLE SWITCH AND USES THEREOF | December 2020 | June 2023 | Abandon | 30 | 1 | 0 | No | No |
| 17119318 | EXOSOMES ISOLATED FROM MESENCHYMAL STEM CELLS AND USES THEREOF | December 2020 | August 2025 | Allow | 56 | 5 | 1 | Yes | No |
| 17251335 | METHOD TO GENERATE INDUCED OLIGODENDROCYTE-LINEAGE CELLS AND TREATMENT USING SUCH CELLS | December 2020 | October 2025 | Allow | 58 | 3 | 1 | Yes | No |
| 16973421 | NEXT GENERATION DESIGNER LIVER ORGANOIDS AND THEIR METHODS OF PREPARATION AND USE | December 2020 | December 2024 | Allow | 48 | 2 | 1 | Yes | No |
| 16972212 | METHODS FOR GENERATING HEMATOPOIETIC STEM CELLS | December 2020 | December 2024 | Allow | 48 | 2 | 1 | Yes | No |
| 17104231 | Gene Therapies, Systems, and Methods for Monitoring | November 2020 | March 2023 | Abandon | 28 | 1 | 0 | No | No |
| 17104607 | METHODS AND COMPOSITIONS FOR INDUCING TUMOR CELL DEATH | November 2020 | April 2023 | Abandon | 29 | 1 | 0 | No | No |
| 16952267 | ARTIFICIAL SKELETAL MUSCLE TISSUE | November 2020 | January 2024 | Abandon | 38 | 2 | 1 | No | No |
| 16951220 | METHODS FOR ENGINEERING HUMAN PLURIPOTENT STEM CELLS FOR DIABETES THERAPY BY CO-TRANSDUCTION | November 2020 | April 2023 | Abandon | 28 | 1 | 0 | No | No |
| 17094219 | NEURON CULTIVATION DEVICE, NEURON CULTIVATING METHOD, CULTIVATED NEURON, ANALYSIS AND IDENTIFICATION OF PROTEIN IN AXON BUNDLE, AND USAGE OF CULTIVATED NEURON | November 2020 | January 2026 | Abandon | 60 | 3 | 1 | Yes | No |
| 17093126 | METHODS OF IN VITRO DIFFERENTIATION OF MIDBRAIN DOPAMINE (MDA) NEURONS | November 2020 | May 2024 | Allow | 42 | 1 | 1 | Yes | No |
| 17091823 | HYPOXIA-INDUCIBLE FACTOR-2A AS A TARGET IN PREVENTION/TREATMENT OF PARKINSON'S DISEASE | November 2020 | February 2023 | Abandon | 28 | 1 | 0 | No | No |
| 17050722 | CRYOPRESERVATION SOLUTION AND CRYOPRESERVATION METHOD | October 2020 | September 2024 | Abandon | 46 | 0 | 1 | No | No |
| 17049543 | NON-HUMAN VERTEBRATE COMPRISING HUMAN LIVER CELLS TRANSPLANTED THEREIN AND METHOD FOR PRODUCING THE SAME | October 2020 | January 2026 | Allow | 60 | 5 | 1 | Yes | No |
| 17048906 | GENERATION OF HUMAN ENDODERMAL ORGANS IN PIG MODEL USING LINEAGE RESTRICTED ENDODERMAL PRECURSORS | October 2020 | July 2025 | Abandon | 57 | 2 | 1 | No | No |
| 17072637 | AAV TRANSFER CASSETTE | October 2020 | January 2026 | Allow | 60 | 6 | 1 | No | No |
| 17071095 | VARIANTS OF CAS12A NUCLEASES AND METHODS OF MAKING AND USE THEREOF | October 2020 | October 2023 | Allow | 36 | 3 | 0 | Yes | No |
| 17046468 | SENSOR FUNCTIONALISED BIOINK | October 2020 | July 2024 | Abandon | 46 | 0 | 1 | No | No |
| 17046248 | CULTURE SCAFFOLD FOR PROMOTING STEM CELL DIFFERENTIATION COMPRISING MULTILAYER GRAPHENE FILM | October 2020 | September 2025 | Allow | 60 | 3 | 1 | Yes | No |
| 17045308 | DRUG SCREENING PLATFORM USING BIOMATERIAL SCAFFOLDS | October 2020 | March 2024 | Abandon | 42 | 1 | 1 | No | No |
| 17043229 | DIFFERENTIATION MEDIUM AND METHOD FOR PREPARING OLIGODENDROCYTE PRECURSOR | September 2020 | July 2024 | Abandon | 46 | 2 | 1 | No | No |
| 17041677 | METHODS OF MODULATING ANTISENSE ACTIVITY | September 2020 | January 2025 | Abandon | 52 | 2 | 0 | No | No |
| 17028139 | MULTIPLEXABLE CRISPR EDITORS UTILIZING INTRACELLULAR EVOLVED APTAMERS FOR ENDOGENOUS EFFECTOR RECRUITMENT | September 2020 | March 2025 | Abandon | 54 | 4 | 1 | Yes | Yes |
| 16948450 | CANINE EPITHELIAL ORGANOIDS AND METHODS OF MAKING, RECOVERING, AND USE | September 2020 | January 2026 | Abandon | 60 | 7 | 1 | Yes | No |
| 17011292 | Humanized Knock-In Mouse Expressing Human Protein C. | September 2020 | October 2023 | Allow | 37 | 2 | 1 | No | No |
| 17001590 | HUMANIZED VIPR2 COPY NUMBER VARIANT TRANSGENIC MOUSE MODEL FOR ANTIPSYCHOTIC DRUG AND GENE THERAPY DISCOVERY FOR SCHIZOPHRENIA | August 2020 | April 2024 | Abandon | 43 | 3 | 0 | No | No |
| 16965835 | ACTIVATION-INDUCED TISSUE-EFFECTOR CELLS SUITABLE FOR CELL THERAPY AND EXTRACELLUAR VESICLES DERIVED THEREFROM | July 2020 | June 2025 | Abandon | 59 | 2 | 1 | No | No |
| 16960812 | EFFICIENT DERIVATION OF STABLE PLURIPOTENT BOVINE EMBRYONIC STEM CELLS | July 2020 | October 2025 | Allow | 60 | 3 | 1 | Yes | No |
| 16833099 | METHOD OF TREATING OR PREVENTING HERNIA FORMATION | March 2020 | January 2024 | Allow | 46 | 5 | 0 | Yes | No |
| 16629485 | BIOSENSORS FOR MEASURING CELL SIGNALING IN STRESSED AND HEALTHY CELLS | January 2020 | February 2024 | Abandon | 49 | 1 | 1 | No | No |
| 16626227 | TRANSGENIC ANIMALS AND TRANSGENIC EMBRYOS PRODUCING AN ENGINEERED NUCLEASE | December 2019 | April 2024 | Allow | 52 | 3 | 0 | Yes | No |
| 16622739 | Genome Editing System For Repeat Expansion Mutation | December 2019 | May 2024 | Abandon | 53 | 4 | 0 | Yes | No |
| 16622509 | UNIVERSAL SELF-REGULATING MAMMALIAN CELL LINE PLATFORM FOR THE PRODUCTION OF BIOLOGICS | December 2019 | March 2024 | Allow | 51 | 2 | 1 | Yes | No |
| 16491208 | COMPOSITION CONTAINING C2CL ENDONUCLEASE FOR DIELECTRIC CALIBRATION AND METHOD FOR DIELECTRIC CALIBRATION USING SAME | December 2019 | April 2023 | Abandon | 43 | 2 | 0 | No | No |
| 16703036 | METHOD FOR PREPARING DIFFERENTIATION-INDUCED CELLS | December 2019 | October 2025 | Abandon | 60 | 7 | 0 | Yes | No |
| 16616216 | CELL CRYOPRESERVATION FORMULATION AND CELL RECOVERY METHOD | November 2019 | February 2025 | Abandon | 60 | 7 | 0 | No | No |
| 16615854 | VIRAL EXPRESSION CONSTRUCT COMPRISING A FIBROBLAST GROWTH FACTOR 21 (FGF21) CODING SEQUENCE | November 2019 | December 2023 | Abandon | 49 | 2 | 1 | No | No |
| 16687426 | HIGH ACTIVITY REGULATORY ELEMENTS | November 2019 | June 2024 | Allow | 55 | 3 | 1 | Yes | No |
| 16604785 | New Uses Of Mammalian Muscle-Derived Stem Cells | October 2019 | February 2024 | Abandon | 53 | 4 | 0 | Yes | No |
| 16484506 | FLUIDIC CHIP FOR CELL CULTURE USE, CULTURE VESSEL, AND CULTURE METHOD | August 2019 | October 2023 | Allow | 50 | 2 | 1 | Yes | No |
| 16527152 | EARLY-ONSET PARKINSON'S DISEASE MODEL: (D331Y) PLA2G6 KNOCKIN MODEL, PLATFORM AND METHOD FOR DRUG SCREENING, AND KIT OF DETECTION | July 2019 | June 2024 | Abandon | 58 | 3 | 1 | No | No |
| 16503481 | Preparation and application of immortalized alpha-1,3-galactosyltransferase gene knockout pig hepatocyte cell line | July 2019 | May 2023 | Abandon | 47 | 1 | 1 | No | No |
| 15960048 | PROMOTERS, EXPRESSION CASSETTES, VECTORS, KITS, AND METHODS FOR THE TREATMENT OF ACHROMATOPSIA AND OTHER DISEASES | April 2018 | May 2024 | Abandon | 60 | 6 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner DHAR, MATASHA.
With a 0.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 0.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner DHAR, MATASHA works in Art Unit 1632 and has examined 71 patent applications in our dataset. With an allowance rate of 42.3%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 46 months.
Examiner DHAR, MATASHA's allowance rate of 42.3% places them in the 8% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by DHAR, MATASHA receive 2.68 office actions before reaching final disposition. This places the examiner in the 78% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by DHAR, MATASHA is 46 months. This places the examiner in the 10% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +48.0% benefit to allowance rate for applications examined by DHAR, MATASHA. This interview benefit is in the 92% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 19.6% of applications are subsequently allowed. This success rate is in the 20% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 22.5% of cases where such amendments are filed. This entry rate is in the 29% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 1% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.
This examiner withdraws rejections or reopens prosecution in 0.0% of appeals filed. This is in the 0% percentile among all examiners. Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.
When applicants file petitions regarding this examiner's actions, 84.6% are granted (fully or in part). This grant rate is in the 86% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 1% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.